IntOGen statistics

Tool stats & trends

Looking to identify usage trends or leading experts?


IntOGen specifications


Unique identifier OMICS_29027
Name IntOGen
Interface Web user interface
Restrictions to use None
Computer skills Basic
Version 2014.12
Stability Stable
Registration required Yes
Maintained Yes


  • person_outline Núria López-Bigas

Publications for IntOGen

IntOGen citations


An integrated clinical and genomic information system for cancer precision medicine

BMC Med Genomics
PMCID: 5918454
PMID: 29697362
DOI: 10.1186/s12920-018-0347-9

[…] t and gene levels. For the in-house curated drugs for actionable targets, we included the FDA-approved drugs, drugs in clinical trials referenced by highly reliable sources such as MyCancerGenome [], IntOGen [], Handbook of targeted cancer therapy [], and manual searches in the New England Journal of Medicine journal. Drugs from text mining were obtained from VarDrugPub [] that identified the vari […]


Proteomic Analysis Shows Constitutive Secretion of MIF and p53 associated Activity of COX 2−/− Lung Fibroblasts

PMCID: 5828655
PMID: 29247872
DOI: 10.1016/j.gpb.2017.03.005

[…] We searched the IntOGen database ( to identify different types of cancers, in which expression of COX-2 and MIF was significantly up-regulated or downregulated, or lost or gained and extracted the da […]


Exome sequencing reveals aberrant signalling pathways as hallmark of treatment naive anal squamous cell carcinoma

PMCID: 5787481
PMID: 29416628
DOI: 10.18632/oncotarget.23066
call_split See protocol

[…] than –0.30 as heterozygous deletion, and less than –1.0 (with a size <5 Mb) as homozygous deletion. Relevant genes affected by a focal gain or deletion of a chromosomal region were selected using the IntOGen database []. […]


Characterization of genetic intratumor heterogeneity in colorectal cancer and matching patient‐derived spheroid cultures

Mol Oncol
PMCID: 5748486
PMID: 29130628
DOI: 10.1002/1878-0261.12156
call_split See protocol

[…] FACETS (Shen and Seshan, ). Tumor purity was estimated using PurBayes (Larson and Fridley, ) and Sequenza (Favero et al., ). Tumor drivers and potentially druggable targets were identified using the IntOGen catalog of cancer drivers, available for download at (Tamborero D, Rubio‐Perez C, Deu‐Pons J, Schroeder M, Vivancos A, Rovira A, Tusquets I, Albanell J, Rodon J, Tabernero J, Diens […]


BioMuta and BioXpress: mutation and expression knowledgebases for cancer biomarker discovery

Nucleic Acids Res
PMCID: 5753215
DOI: 10.1093/nar/gkx907

[…] Raw data was downloaded from several repositories including TCGA, the Catalog of Somatic Mutations in Cancer (COSMIC) (), ICGC, IntOGen () and ClinVar. UnitProtKB/Swiss-Prot () resource was used as a source for both variation and annotation data. Some of the data sources offer alternate versions of the same data depending on i […]


Identification of potentially oncogenic alterations from tumor only samples reveals Fanconi anemia pathway mutations in bladder carcinomas

PMCID: 5677944
PMID: 29263839
DOI: 10.1038/s41525-017-0032-5

[…] in the gradient boosting model, weighted and scaled so that the sum of relative influence of all features equals one hundred.We defined drivers in Fig. using the list of driver genes provided by the Intogen group. The rate of somatic SNVs per Mb for each case was calculated using the number of published somatic SNVs, after converting di-nucleotide mutations into single nucleotide components and r […]


Looking to check out a full list of citations?

IntOGen institution(s)
Biomedical Genomics Lab, Research Program on Biomedical Informatics, IMIM Hospital del Mar Medical Research Institute and Universitat Pompeu Fabra, Barcelona, Catalonia, Spain; Systems Pharmacology, Research Program on Biomedical Informatics, IMIM Hospital del Mar Medical Research Institute and Universitat Pompeu Fabra, Barcelona, Catalonia, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain
IntOGen funding source(s)
Supported by the Spanish Ministry of Economy and Competitiveness (grant number SAF2012-36199), La Fundacio la Marato de TV3, and the Spanish National Institute of Bioinformatics (INB); an FPI fellowship; the People Programme (Marie Curie Actions) of the Seventh Framework Programme of the European Union (FP7/2007- 2013) under REA grant agreement number 600388 and by the Agency of Competitiveness for Companies of the Government of Catalonia, ACCIO and by a Ramon y Cajal contract.

IntOGen reviews

star_border star_border star_border star_border star_border
star star star star star

Be the first to review IntOGen